Ion channel blockers for the treatment of neuropathic pain

Future Medicinal Chemistry

Volumn 2, Issue 5, 2010, Pages 803-842

  Colombo, Elena ^a   Francisconi, Simona ^a   Faravelli, Laura ^a   Izzo, Emanuela ^a   Pevarello, Paolo ^a  

^a Newron Pharmaceuticals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; A 803467; AMPA RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CYCLIC NUCLEOTIDE GATED CHANNEL; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; ETHOSUXIMIDE; FLUPIRTINE; GABAPENTIN; ICA 105665; ICA 27243; ION CHANNEL; LECONOTIDE; LIDOCAINE ETHOBROMIDE; MIBEFRADIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OMEGA CONOTOXIN MVIIA; POTASSIUM CHANNEL AFFECTING AGENT; PREGABALIN; QUTENZA; RALFINAMIDE; RETIGABINE; SODIUM CHANNEL BLOCKING AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

BRAIN DAMAGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NERVE CELL; NERVE EXCITABILITY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; ION CHANNELS; MEMBRANE TRANSPORT MODULATORS; NEURALGIA;

EID: 77953417920     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.19     Document Type: Review

References (407)

1. IASP Council in Kyoto. IASP Terminology. Modified and improved for publication in Kyoto, Japan, 29-30 November (2007).
2. Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Exp. Opin. Emerg. Drugs 12 (1), 113-126 (2007).
3. Baron R. Mechanisms of disease: neuropathic pain - a clinical perspective. Nat. Clin. Pract. 2 (2), 95-106 (2006).
4. Janig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet Neurol. 2, 687-697 (2003).
5. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6, 521-532 (2005).
6. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth. Analg. 97 (4), 1108-1116 (2003).
7. Qu XX, Cai J, Li MJ et al. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp. Neurol. 215 (2), 298-307 (2009).
8. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 14, 166-174 (2005).
9. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23-36 (2009).
10. Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J. Pain 7 (1S), S38-S47 (2006).
11. Matulenko MA, Scanio M J C, Kort, ME. Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr. Top. Med. Chem. 9, 362-376 (2009).
12. Burnstock G. Purinergic receptors and pain. Curr. Pharm. Des. 15 (15), 1717-1735 (2009).
13. Cortright DN, Szallasi A. TRP channels and pain. Curr. Pharm. Des. 15 (15), Very useful and informative review on the role of transient receptor potential channels in pain transduction.
14. Dubé GR, Elagoz A, Mangat H. Acid sensing ion channels and acid nociception. Curr. Pharm. Des. 15 (15), 1750-1766 (2009).
15. Dunlop J, Vasilyev D, Lu P et al. Hyperpolarization-activated cyclic nucleotidegated (HCN) channels and pain. Curr. Pharm. Des. 15 (15), 1767-1772 (2009).
16. v7 channels.
17. Dray A. Neuropathic pain: emerging treatments. Br. J. Anaesth. 101 (1), 48-58 (2008). Useful reference for a broad overview of current and future neuropathic pain treatments.
18. + channels subtypes as pain targets and the influence of their biophysical properties on pain conditions.
19. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structurefunction relationships of voltage-gated sodium channels. Pharmacol. Rev. 57, 397-409 (2005). Key reference providing an overview of the general properties, physiological role and pharmacological significance of the voltage gated sodium channel.
20. Chahine M, Chatelier A, Babich O et al. Voltage-gated sodium channels in neurological disorders. CNS & Neurological Disorders - Drug Targets 7, 144-158 (2008).
21. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 131 (3), 243-257 (2007).
22. Priest BT. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr. Opin. Drug Discov. & Develop. 12 (5), 682-692 (2009).
23. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not in adult spinal sensory neurons, and is re-expressed following axotomy. J. Neurophysiol. 72, 466-470 (1994).
24. v1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23, 8881-8892 (2003).
25. Hains BC, Saab CY, Klein JP et al. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J. Neurosci. 24, 4832-4839 (2004).
26. Coward K, Aitken A, Powell C et al. Plasticity of TTX-sensitive sodium channels PNI and brain III in injured human nerves. Neuroreport 12, 495-500 (2001).
27. Black JA, Nikolajsen L, Kroner K et al. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol. 64 (6), 644-653 (2008).
28. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17, 3503-3514 (1997).
29. vv1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21, 5952-5961 (2001).
30. Lampert A, Hains BC, Waxman SG. Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury. Exp. Brain Res. 174, 660-666 (2006).
31. v1.3 expression and neuropathic pain behavior in rats. Pain 117, 145-153 (2005).
32. v1.3 null mutant mice. Mol. Pain 2, 33 (2006).
33. v1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128 (8), 1847-1854 (2005).
34. v1.7 underlie inherited erythromelalgia. Drug Discov. Today 3 (3), 343-350 (2006).
35. v1.7 and human pain disorders. Trends Neurosci. 30 (11), 555-563 (2007).
36. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117 (12), 3603-3609 (2007).
37. Fertleman CR, Baker MD, Parker KA et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767-774 (2006).
38. v1.7 gene determine congenital insensitivity to pain.
39. v1.7 channel and congenital indifference to pain and provides a thorough clinical description of the congenital indifference to pain phenotype.
40. v1.8. Mol. Pain 1, 24 (2005).
41. v1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. USA 101, 12706-12711 (2004).
42. v1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J. Neurosci. 26, 12566-12575 (2006).
43. Rush AM, Dib-Hajj SD, Liu S et al. A single sodium channel mutation produces hyperor hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. USA 103, 8245-8250 (2006).
44. Rush AM, Cummins TR, Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J. Physiol. (London) 579 (1), 1-14 (2007). Illustrates how excitability can be finely tuned by complementary expression of different sodium channel types to provide contrasting firing templates in different subclasses of dorsal root ganglion neurons.
45. Elliott AA, Elliott JR. Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells from adult rat dorsal root ganglia. J. Physiol. 463, 39-56 (1993).
46. Akopian AN, Souslova V, England S et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 2, 541-548 (1999).
47. v1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86, 629-640 (2001).
48. Black JA, Liu S, Tanaka M et al. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108, 237-247 (2004).
49. + current in nociceptors. Proc. Natl. Acad. Sci. USA 93, 1108-1112 (1996).
50. v1.8. Pain 95, 143-152 (2002).
51. Dib-Hajj S, Black JA, Felts P et al. Downregulation of transcripts for Na channel a-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA 93, 14950-14954 (1996).
52. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 17, 3503-3514 (1997).
53. Dib-Hajj SD, Fjell J, Cummins TR et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83, 591-600 (1999).
54. Novakovic SD, Tzoumaka E, McGivern JG et al. Distribution of the tetrodotoxinresistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J. Neurosci. 15, 18 (6) 2174-2187 (1998).
55. v1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 23, 158-166 (2003).
56. Cummins TR, Dib-Hajj SD, Black JA et al. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 19, RC43 (1999).
57. v1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol. 550, 921-926 (2003).
58. Porreca F, Lai J, Bian D et al. A comparison of the potential role of the tetrodotoxininsensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc. Natl Acad. Sci. USA 96, 7640-7644 (1999).
59. v1.9 to sensory transmission and nociceptive behavior. Proc. Natl Acad. Sci. USA 102, 9382-9387 (2005).
60. v1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 26, 12852-12860 (2006).
61. Eisenberg E, River Y, Shifrin A et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67 (9), 1265-1289 (2007).
62. Sindrup HJ, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83, 389-400 (1999).
63. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry 29 (3), 265-267 (1966).
64. Sindrup, SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin. J. Pain 18, 22-27 (2002).
65. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S. Afr. Med. J. 48 (20), 869-872 (1974).
66. Gomez-Perez FJ, Choza R, Rios JM et al. Nortriptyline-fluphenazine vs carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch. Med. Res. 27, 525-529 (1996).
67. Sindrup SJ, Jensen TS. Are sodium channel blockers useless in peripheral neuropathic pain? aPain 128, 6-7 (2007).
68. Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurother. 6 (4), 663-678 (2009).
69. Cummins TR, Rush AM. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Exp. Rev. Neurother. 7 (11), 1597-1612 (2007).
70. Priest BT, Kaczorowski GJ. Blocking sodium channels to treat neuropathic pain. Expert Opin. Ther. Targets 11 (3), 291-306 (2007).
71. Jain KK. Current challenges and future prospects in management of neuropathic pain. Expert Rev. Neurother. 8 (11), 1743-1756 (2008).
72. Bear B, Asgian J, Termin A, Zimmermann N. Small molecules targeting sodium and calcium channels for neuropathic pain. Curr. Opin. Drug Discov. Develop. 12 (4), 543-561 (2009). Updated and thorough review of the new trends in the medicinal chemistry of sodium and calcium channel blockers.
73. Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature 447, 607-611 (2007).
74. th Annual Meeting of the Society for Neuroscience. Atlanta, GA, USA, 14-18 October 2006 (Abstract 245.11).
75. Catterall WA, Perez-Reyes E, Snutch T P, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltagegated calcium channels. Pharmacol. Rev. 57 (4), 411-425 (2005). Key reference overview of the general properties, physiological role and pharmacological significance of the voltage-gated cation channel.
76. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 147, 456-463 (2002).
77. Luo ZD, Chaplan SR, HigueraES et al. Upregulation of dorsal root ganglion (α) 2 (δ) calcium channel subunit and its correlation with allodynia in spinal nerve injured rats. J. Neurosci. 21 (6), 1868-1875 (2001).
78. 2+ channels with gene knockout models. Channels 2 (4), 1-19 (2008).
79. Kim C, Jun. K, Lee T et al. Altered nociceptive response in mice deficient in the α (1B) subunit of the voltage-dependent calcium channel. Mol. Cell. Neurosci. 18, 235-245 (2001).
80. 2+ channel. EMBO J. 20, 2349-2356 (2001).
81. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin. Pharmacother. 9 (9), 1575-1583 (2008). Recent review reporting information about pharmacokinetic properties, safety aspects and clinical efficacy of ziconotide.
82. Vitale V, Battelli D, Gasperoni E, Monachese N. Intrathecal therapy with ziconotide: clinical experience and consideration on its use. Minerva Anestesiol. 74, 727-733 (2008).
83. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev. 8 (3), CD007076 (2009). Database collection of available information from clinical trials to assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain.
84. Noor M, Gajraj NM. Pregabalin: its pharmacology and use in pain management Anesth. Analg. 105 (6), 1805-1815 (2007).
85. McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging 26 (10), 883-892 (2009).
86. vα2-δ] ligands. Pain 142 (1-2), 13-16 (2009).
87. 2-δ subunits of voltage-gated calcium channels. aTrends Pharmacol. Sci. 28 (5), 220-228 (2007).
88. Heblich F, Tran Van Minh A, Hendrich J, Watschinger K, Dolphin AC. Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin. Channels 2 (1), 4-9 (2008).
89. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. 83, 117-161, (2003).
90. Jagodic MM, Pathirathna S, Joksovic PM et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J. Neurophysiol. 99, 3151-3156 (2008).
91. Jagodic MM, Pathirathna S, Nelson MT et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J. Neurosci. 27 (12), 3305-3316 (2007).
92. Todorovic SM, Jevtovic-Todorovic V. Regulation of T-type channels in the peripheral pain pathway. Channels 4, 238-245 (2007).
93. McCallum JB, Kwok WM, Mynlieff M, Bosnjak ZJ, Hogan QH. Loss of T-type calcium current in sensory neurons of rats with neuropathic pain. Anesthesiology 98, 209-216 (2003).
94. Wolfart J, Roeper J. Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J. Neurosci. 22, 3404-3413 (2002).
95. Mircea C. Iftinca MC, Zamponi GW. Regulation of neuronal T-type calcium channels. Trends Pharmacol. Sci. 30 (1), 32-40 (2009).
96. v3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 24, 315-324 (2005).
97. Belardetti F, Zamponi GW. Linking calcium channel isoforms to potential therapies Curr. Opin. Invest. Drugs 7, 707-715 (2008). Comprehensive overview of progress in the development of calcium channel therapeutics in the pain therapeutic area.
98. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth. Analg. 6, 1805-1815 (2007).
99. Kolosov A, Goodchild CS, Cook I et al. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 11, 262-273 (2010).
100. Yamamoto T, Takahara A. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr. Top. Med. Chem. 9, 377-395 (2009).
101. Gutman GA, Chandy KG, Grissmer S et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 57, 473-508 (2005).
102. Wei AD, Gutman GA, Aldrich R et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol. Rev. 57, 463-472 (2005).
103. Kubo Y, Adelman JP, Clapham DE et al. International Union of Pharmacology. LIV. Nomenclature and molecular relationships of inwardly rectifying potassium channels. Pharmacol. Rev. 57, 509-526 (2005).
104. Goldstein S A N, Bayliss DA, Kim D et al. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol. Rev. 57, 527-540 (2005).
105. Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens, JM. Potassium channels and pain: present realities and future opportunities. Eur. J. Pharmacol. 500, 203-219 (2004).
106. Chien L-Y, Cheng J-K, Chu D, Cheng C-F, Tsaur M-L. Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity. J. Neurosci. 27 (37), 9855-9865 (2007).
107. v4 channels underlie the subthreshold-operating A-type K-current in nociceptive dorsal root ganglion neurons. Front. Mol. Neurosci. 2, 3 (2009).
108. Chen SR, Cai YQ, Pan HL. Plasticity and emerging role of BKCa channels in nociceptive control in neuropathic pain. J. Neurochem. 110 (1), 352-362 (2009).
109. Rivera-Arconada I, Roza C, Lopez-Garcia JA. Enhancing M currents: a way out for neuropathic pain? Front Mol Neurosci. 2, 10 (2009).
110. Jiang YQ, Sun Q, Tu HY, Wan Y. Characteristic of HCN channels and their participation in neuropathic pain. Neurochem. Res. 33, 1979-1989 (2008). Recent review about hyperpolarization activated cyclic nucleotide gated cation channels structure and evidence of its role in neuropathic pain.
111. Noma A, Irisawa H. Membrane currents in the rabbit sinoatrial node cell as studied by the double microelectrode method. Pflugers Arch. 364 (1), 45-52 (1976)
112. Chaplan SR, Guo HQ, Lee DH et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J. Neurosci. 23, 1169-1178 (2003).
113. Sun Q, Xing GG, Tu HY, Han JS, Wan Y. Inhibition of hyperpolarization- activated current by ZD7288 suppresses ectopic discharges of injured dorsal root ganglion neurons in a rat model of neuropathic pain. Brain Res. 1032 (1-3), 63-69 (2005).
114. Mayer ML, Westbrook GL. A voltage-clamp analysis of inward (anomalous) rectification in mouse spinal sensory ganglion neurones. J. Physiol. 340, 19-45 (1983).
115. Kouranova EV, Strassle BW, Ring RH, Bowlby MR, Vasilyev DV. Hyperpolarization Activated cyclic nucleotide-gated channel mRNA and protein expression in large versus small diameter dorsal root ganglion neurons: correlation with hyperpolarization-activated current gating. Neuroscience 153 (4), 1008-1019 (2008).
116. Tu H, Deng L, Sun Q, Yao L, Han JS, Wan Y. Hyperpolarization-activated, cyclic nucleotide-gated cation channels: roles in the differential electrophysiological properties of rat primary afferent neurons. J. Neurosci. Res. 76 (5), 713-722 (2004).
117. Papp I, Szucs P, Hollo K, Erdelyi F, Szabo G, Antal M. Hyperoplarization-activated and cyclic nucleotide-gated cation channel subunit 2 ion channels modulate synaptic transmission from nociceptive primary afferents containing substance P to secondary sensory neurons in laminae I-IIo of the rodent spinal dorsal horn. Eur. J. Neurosci. 24, 1341-1352 (2006).
118. Luo L, Chang L, Brown SM et al. Role of peripheral hyperpolarization- activate cyclic nucleotide-modulated channel pacemaker channels in acute and chronic pain models in the rat. Neuroscience 144, 1477-1485 (2007).
119. Bie B, Peng Y, Zhang Y, Pan ZZ. cAMP-mediated mechanism for pain sensitization during opioid withdrawal. J. Neurosci. 25 (15), 3824-3832 (2005).
120. Jolas T, Nestler EJ, Aghajanian GK. Chronic morphine increases GABA tone on serotoninergic neurons of the dorsal raphe nucleus: association with an upregulation of the cyclic AMP pathway. Neuroscience 95 (2), 433-443 (2000).
121. Brown SM, Dubin AE, Chaplan SR. The role of pacemaker currents in neuropathic pain. Pain Practice 4 (3), 182-193 (2004).
122. Devor M, Raber P. Autotomy after nerve injury and its relation to spontaneous discharge originating in nerve-end neuromas. Behav. Neurol. Biol. 37, 276-283 (1983).
123. Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain 85, 503-521 (2000).
124. Tal M, Eliav E. Abnormal discharge originates at the site of nerve injury in experimental constriction neuropathy (CCI) in the rat. Pain 64 (3), 511-518 (1996).
125. Kajander KC, Bennett GJ. Onset of a painful peripheral neuropathy in rat: a partial and differential deafferentation and spontaneous discharge in A-β and A-δ primary afferent neurons. J. Neurophysiol. 68 (3), 734-744 (1992).
126. Song XJ, Hu SJ, Greenquist K W, Zhang JM, LaMotte RH. Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia. J. Neurophysiol. 82 (6), 3347-3358 (1999).
127. Wan Y. Involvement of hyperpolarization activated cyclic nucleotide-gated cation channels in dorsal root ganglion in neuropathic pain. Acta Physiol. Sinica 60 (5), 579-580 (2008).
128. Yao H, Donnelly DF, Ma C, LaMotte RH. Upregulation of the hyperpolarization activated cation current after chronic compression of the dorsal root ganglion. J. Neurosci. 23, 2069-2074 (2003).
129. Jiang YQ, Xing GG, Wang SL et al. Axonal accumulation of hyperpolarization-activated cyclic nucleotide-gated cation channels contributes to mechanical allodynia after peripheral nerve injury in rat. Pain 137, 495-506 (2008).
130. Lee DH, Chang L, Sorkin LS, Chaplan SR. Hyperpolarization-activated, cationnonselective, cyclic nucleotide-modulated channel blockade alleviates mechanical allodynia and suppresses ectopic discharge in spinal nerve ligated rats. J. Pain. 6 (7), 417-424 (2005).
131. Hellwig N, Albrech N, Harteneck C, Schultz G, Schaefer M. Homo- and heteromeric assembly of TRPV channel subunits. J. Cell Sci. 118, 917-928 (2005).
132. Salazar H, Jara-Oseguera A, Hernandez-Garcia E et al. Structural determinants of gating in the TRPV1 channel. Nat. Struct. Mol. Biol. 16 (7), 704-710 (2009).
133. Montell C. The TRP superfamily of cation channels. Science STKE 272, 3 (2005).
134. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824 (1997).
135. Tominaga M, Caterina MJ, Malmberg AB et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. aNeuron 21, 531-543 (1998).
136. Xu H, Blair NT, Clapham DE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. J. Neurosci. 25, 8924-8937 (2005).
137. Macpherson LJ, Geierstanger BH, Viswanath V et al. The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr. Biol. 15, 929-934 (2005).
138. Yoshida T, Inoue R, Morii T et al. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat. Chem. Biol. 2 (11), 596-607 (2006).
139. Trevisani M, Smart D, Gunthorpe MJ et al. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat. Neurosci. 5, 546-551 (2002).
140. Lee SY, Lee JH, Kang KK, Hwang SY, Choi KD, Oh U. Sensitization of vanilloid receptor involves an increase in the phosphorylated form of the channel. Arch. Pharm. Res. 28, 405-412 (2005).
141. Sanchez JF, Krause JE, Cortright DN. The distribution and regulation of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat. Neuroscience 107, 373-381 (2001).
142. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 24, 487-517 (2001).
143. Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur. J. Neurosci. 13, 2105-2114 (2001).
144. Caterina MJ, Leffler A, Malmberg AB et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306-313 (2000).
145. Davis JB, Gray J, Gunthorpe MJ et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183-187 (2000).
146. Christoph T, Gillen C, Mika J et al. Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem. Int. 50, 281-290 (2007).
147. Christoph T, Grunweller A, Mika J et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem. Biophys. Res. Commun. 350, 238-243 (2006).
148. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A. Involvement of an increased spinal TRPV1 sensitization through its upregulation in mechanical allodynia of CCI rats. Neuropharmacol. 49, 977-984 (2005).
149. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N- (4-Tertiarybutylphenyl) -4- (3-chloropyridin-2-yl) tetrahydropyrazine-1 (2H) -carbox-amide (BCTC), a novel, orally-effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 306, 387-393 (2003).
150. Honore P, Wismer CT, Mikusa J et al. A-425619 [1-isoquinolin-5-yl-3- (4-trifluoromethyl-benzyl) -urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther. 314, 410-421 (2005).
151. Smith GD, Gunthorpe MJ, Kelsell RE et al. TRPV3 is a temperature sensitive vanilloid receptor-like protein. Nature 418, 186-190 (2002).
152. Xu H, Ramsey IS, Kotecha SA et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 418, 181-186 (2002).
153. Hu HZ, Xiao R, Wang C et al. Potentiation of TRPV3 channel function by unsaturated fatty acids. J. Cell. Physiol. 208, 201-212 (2006).
154. Peier AM, Reeve AJ, Andersson DA et al. A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046-2049 (2002).
155. Moqrich A, Hwang SW, Earley TJ et al. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307, 1468-1472 (2005).
156. Gullapalli S, Thomas A, Rao P, Kattige V, Gudi GS, Khairatkar-Joshi N. GRC-15133: a novel, selective TRPV3 antagonist with antihyperalgesic effects in inflammatory and neuropathic pain. CHI's World Pharmaceutical Congress, Philadelphia, PA, USA, 2008.
157. Jaquemar D, Schenker, Trueb B. An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts. J. Biol. Chem. 274, 7325-7333 (1999).
158. Bandell M, Story GM, Hwang SW et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41, 849-857 (2004).
159. Taylor-Clark TE, Undem BJ, Macglashan DW, Ghatta S, Carr MJ, McAlexander MA. Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1). Mol. Pharmacol. 73, 274-281 (2008).
160. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacker J, Hricik TR. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829 (2003).
161. Obata K, Katsura H, Mizushima T, Yamanaka H, Kobayashi K, Day Y. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J. Clin. Invest. 115, 2393-2401 (2005).
162. Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124, 1269-1282 (2006).
163. Katsura H, Obata K, Mizushima T, Yamanaka H, Kobayashi K, Day Y. Antisense knock-down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp. Neurol. 200, 112-113 (2006).
164. Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacol. 56, 90-113 (2009).
165. Petrus M, Peier AM, Bandell M et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol. Pain 3, 40 (2007).
166. McNamara CR, Mandel Brehm J, Bautista DM et al. TRPA1 mediates formalin-induced pain. Proc. Natl. Acad. Sci. USA 104, 13525-13530 (2007).
167. Eid SR, Crown ED, Moore EL et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathyinduced mechanical hypersensitivity. Mol. Pain 4, 48 (2008).
168. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM. A TRP channel that senses cold stimuli and menthol. Cell 108, 705-715 (2002).
169. Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448, 204-208 (2007).
170. McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416, 52-58 (2007).
171. Kobayashi A, Fukuoka T, Obata H et al. Distinct expression of TRPM8, TRPA1 and TRPV1 mRNAs in rat primary afferent neurons with Aδ/C-fibers and colocalization with Trk receptors. J. Comp. Neurol. 493, 596-606 (2005).
172. Colburn RW, Lubin ML., Stone DJ, Wang Y, Lawrence D, D'Andrea MR. Attenuated cold sensitivity in TRPM8 null mice. Neuron 54, 379-386 (2007).
173. Dhaka A, Murray AN, Mathur J, Earley TJ, Petrus MJ, Patapoutian A. TRPM8 is required for cold sensation in mice. Neuron 54, 371-378 (2007).
174. Proudfoot CJ, Garry EM, Cottrell DF et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 16, 1591-1605 (2006).
175. Xing H, Chen M, Ling J, Tan W, Gu JG. TRPM8 mechanism of cold allodynia after chronic nerve injury. J. Neurosci. 2 7, 13680-13690 (2007).
176. Caspani O, Zurborg S, Labuz D, Heppenstall PA. The contribution of TRPM8 and TRPA1 channels to cold allodynia and neuropathic pain. PloS ONE 4 (10), e7383 (2009).
177. Szallasi A, Appendino G. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse? J. Med. Chem. 47 (11), 2717-2723 (2004).
178. Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J. Med. Chem. 50, 2589-2596 (2007).
179. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6, 357-372 (2007).
180. Starowicz K, Cristino L, DiMarzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Phar. Des. 14, 42-54 (2008).
181. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res. Rev. 60, 267-277 (2009).
182. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends. Pharm. Sci. 29 (11), 550-557 (2008).
183. Salter M. W. Cellular signaling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr. Top. Med. Chem. 5, 557-567 (2005).
184. Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin. Cell. Dev. Biol. 17, 592-604 (2007).
185. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacol. 56, 2-5 (2009).
186. Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu. Rev. Physiol. 66, 161-181 (2004).
187. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7 (1), 39-47 (2007).
188. Childers WE Jr, Baudy RB. N-methyl-D-aspartate antagonists and neuropathic pain: the search for relief. J. Med. Chem. 50 (11), 2557-2562 (2007). Excellent review on the pros and cons of different N-methyl-d-aspartate antagonists in neuropathic pain.
189. Yaksh TL, Sorkin LS. Mechanism of neuropathic pain. Curr. Med. Chem. CNS Agents 11, 2977-2994 (2005).
190. Zhou S, Bonasera L, Carlton SM. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport 7, 895-900 (1996).
191. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalininduced tissue injury. J. Neurosci. 12, 3665-3670 (1992).
192. Karlsson U, Sjodin J, Angeby K et al. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn. Effects of pheriperal nerve lesion and inflammation. Neuroscience 112, 861-868 (2002).
193. Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in "windup" of class 2 neurones in the dorsal horn of the rat. Brain Res. 424, 402-406 (1987).
194. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurons following C fibre stimulation. Neuropharmacol. 26, 1235-1238 (1987).
195. Brown DG, Krupp JJ. N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr. Top. Med. Chem. 6, 749-770 (2006).
196. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain - multiple drug targets and multiple uses. Curr. Pharm. Des. 11, 2977-2994 (2005).
197. Mony L, Kew J N C, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanism and therapeutic potential. Br. J. Pharmacol. 157, 1301-1317 (2009).
198. Morales-Alcelay S, Rubio L, Martinez A. AMPA glutamate receptors and neuropathic pain. Minirev. Med. Chem. 3, 757-763 (2003).
199. Garry EM, Moss A, Rosie R et al. Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit. Mol. Cell. Neurosci. 24, 10-22 (2003).
200. Harris JA, Corsi M, Quartiroli M, Arban R, Bentivoglio M. Upregulation of spinal glutamate receptors in chronic pain. Neuroscience 74, 7-12 (1996).
201. Bennett AD, Everhart AW, Hulsebosch CE. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res. 859, 72-82 (2000).
202. Szekely JI, Torok K, Maté G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding site. Curr. Pharm. Des. 8, 887-912 (2002).
203. Donevan SD, Rogawski MA. GYKI52466, a 2, 3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10, 51-59 (1993).
204. Gilron I, Max MB, Lee G et al. Effects of the 2-amino-3-hydroxy-5-methyl- 4-isoazolepropionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 68, 320-327 (2000).
205. Gormsen L, Finnerup NB, Almqvist PM, Jensen TS. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, doubleblind, placebo-controlled, three-way crossover study. Anesth. Analg. 108, 1311-1319 (2009).
206. Sato K, Kiyama H, Park HT, Tohyama M. AMPA, KA and NMDA receptors are expressed in the rat DRG neurons. Neuroreport 4, 1263-1265 (1993).
207. Giovengo SL, Kitto KF, Kurtz HJ, Velazquez RA, Larson AA. Parenterally administered kainic acid induces a persistent hyperalgesia in the mouse and rat. Pain 111, 151-161 (1999).
208. Procter MJ, Houghton AK, Faber ES et al. Actions of kainate and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacol. 37, 1287-1297 (1998).
209. Alt A, Weiss B, Ogden AM et al. Pharmacological characterization of glutamatergic agonist and antagonist at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacol. 46, 793-806 (2004).
210. Palecek J, Neugebauer V, Carlton SM, Ivengar S, Willis WD. The effect of kainate GluR5 receptor antagonist on responses of spinothalamic neurons in a model of peripheral neuropathy in primates. Pain 111, 151-161 (2004).
211. Wu L, Ko SW, Zhuo M. Kainate receptors and pain: from dorsal root ganglion to the anterior cingulated cortex. Curr. Pharm. Des. 13, 1597-1605 (2007).
212. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 87, 659-797 (2007).
213. Burnstock G, Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J. Pharmacol. Exp. 295 862-869 (2000).
214. North RA. Molecular physiology of P2X receptors. Physiol. Rev. 82, 1013-1067 (2002).
215. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature 442 527-532 (2006).
216. North RA, Suprenant A. Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 40, 563-580 (2000).
217. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552 (2001).
218. Burnstock G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64, 1471-1483 (2007).
219. 7 heteromeric receptors. Mol. Pharmacol. 72, 1447-1456 (2007).
220. Jones CA, Vial C, Sellers LA et al. Functional regulation of P2X6 receptors by N-linked glycosylation: identification of novel α:β-methylene ATP-sensitive phenotype. Mol. Pharmacol. 65 (4), 979-985 (2004).
221. Holton FA, Holton PJ. The capillary dilator substances in dry powders of spinal roots; a possible role for adenosine triphosphate in chemical transmission from nerve endings. J. Physiol. 126, 124-140 (1954).
222. Holton PJ. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J. Physiol. 145, 494-504 (1959).
223. Jahr CE, Jessell TM. ATP excites a subpopulation of rat dorsal horn neurones. Nature 304, 730-733 (1983).
224. Nakagawa T, Wakamatsu K, Zhang N et al. Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the phase of the induction and maintenance. Neuroscience 147, 445-455 (2007).
225. Bleehen T, Keele CA. Observation on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3, 367-377 (1977).
226. Hamilton SG, Warburton J, Bhattacharjee A, Ward J, McMahon SB. ATP in human skin elicits a dose-related pain response under conditions of hyperalgesia. Brain 123, 1238-1246 (2000).
227. Jarvis MF. Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain. Exp. Opin. Ther. Targets 7, 513-522 (2003).
228. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Ther. 109, 210-226 (2006).
229. Donnelly-Roberts D, McGaraughty S, Shieh CC, Honore P, Jarvis MF. Painful purinergic receptors. J. Pharmaol. Exp. Ther. 324, 409-415 (2008). Comprehensive and very useful review on the role of P2X receptors in pain.
230. Ahrens J, Leuwer M, Reyhan D et al. Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine a1- and α1β-receptors. Naunyn Schmied. Arch. Pharmacol. 379 (4), 371-378 (2009).
231. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol. Sci. 22, 182-188 (2001).
232. Shinoda M, Kawashima K, Ozaki N, Asai H, Nagamine K, Sugiura Y. P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain. J. Pain 8, 588-597 (2007).
233. Cockayne DA, Hamilton SG, Zhu QM et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407, 1011-1015 (2000).
234. Souslova V, Cesare P, Ding Y et al. Warmcoding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 407, 1015-1017 (2000).
235. 3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 99, 11-19 (2002).
236. Dorn G, Patel S, Wotherspoon G et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004).
237. Honore P, Mikusa J, Bianchi B et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 96, 99-105 (2002).
238. Kim C, Chung JM, Chung K. Changes in the gene expression of six subtypes of P2X receptors in rat dorsal root ganglion after spinal nerve ligation. Neurosci. Lett. 337, 81-84 (2003).
239. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Ther. 109, 210-226 (2006).
240. 7). Science 272, 735-738 (1996).
241. Nuttle LC, Dubyak GR. Differential activation of cation channels and non-selective pores by macrophage P2z purinergic receptors expressed in Xenopus oocytes. J. Biol. Chem. 269 (19), 13988-13996 (1994).
242. Hide I, Tanaka M, Inoue A et al. Extracellular ATP triggers tumor necrosis factor-α release from rat microglia. J. Neurochem. 75, 965-972 (2000).
243. Sanz JM, Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1 β release from microglial cells. J. Immunol. 164, 4893-4898 (2000).
244. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 24: 450-455 (2001).
245. 7 receptor -/- mice. Neuroreport 15, 2387-2391 (2004).
246. Chessell IP, Hatcher JP, Bountra C et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114: 386-396 (2005).
247. 7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319: 1376-1385 (2006).
248. Lingueglia E. Acid-sensing ion channels in sensory perception. J. Biol. Chem. 282 (24), 17325-17329 (2007).
249. Gonzales EB, Kawate T, Gouaux E. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature 460, 599-605 (2009).
250. Reyhan D, Leuwer M, de la Roche J et al. Modulation of glycine receptor function by the synthetic cannabinoid HU210. Pharmacology 83 (5), 270-274 (2009).
251. Holzer P. Acid sensor ion channels and receptors. Handb. Exp. Pharmacol. 194, 283-332 (2009).
252. Lindahl O. Pain: a chemical explanation. Acta Rheumatol. Scand. 8, 161-169 (1962).
253. Reeh PW, Steen KH. Tissue acidosis in nociception and pain. Prog. Brain Res. 113, 143-151 (1996).
254. Voilley N, De Weille J, Mamet J, Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation induced expression of acid-sensing ion channels in nociceptors. J. Neurosci. 21 (20), 8026-8033 (2001).
255. Mamet J, Baron A, Lazdunsky M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J. Neurosci. 22 (24), 10662-10670 (2002).
256. Ferreira J, Santos AR, Calixto JB. Antinociception produced by systemic, spinal and supraspinal administration of amiloride in mice. Life Sci. 65 (10), 1059-1066 (1999).
257. Xu TL, Duan B. Calcium-permeable acid-sensing ion channel in nociceptive plasticity: a new target for pain control. Prog. Neurobiol. 87, 171-180 (2009).
258. Poirot O, Berta T, Decosterd I, Kellenberger S. Distinct ASIC currents are expressed in rat putative nociceptors and are modulated by nerve injury. J. Physiol. 576 (1), 215-234 (2006).
259. Mazzuca M., Heurteaux C, Alloui A et al. A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat. Neurosci. 10 (8), 943-945 (2007). Recent key work outlining the proof of concept of the usefulness of acid-sensing ion channel 1a blockers in the treatment of neuropathic pain.
260. A modulators for neuropathic pain.
261. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv. Pharmacol. 54, 1-27 (2006).
262. A receptor subtypes. Adv. Pharmacol. 54, 231-263 (2006).
263. A receptors: evidence for peripheral primary afferent depolarization. Neuroscience 93 (2), 713-722 (1999).
264. A-receptor subtypes in the spinal cord: an immunohistochemical study. J. Neurosci. 16 (1), 283-297 (1996).
265. Melzack R, Wall P. D. Pain mechanism: a new theory. Science 150, 971-979 (1965).
266. Kaneko M, Hammond DL. Role of spinal γ-aminobutyric acid A receptors in formalininduced nociception in the rat. J. Pharmacol. Exp Ther. 282 (2), 928-938 (1997).
267. B receptor pharmacology in a rat model of neuropathic pain. Anesthesiology 96, 1161-1167 (2002).
268. A receptor agonists in the rat spared nerve injury model of neuropathic pain. Eur. J. Pharmacol. 516, 131-138 (2005).
269. A receptor modulation in dorsal root ganglia in vivo affects chronic pain after nerve injury. Neuroscience 154, 1539-1553 (2008).
270. Hwang JH, Yaksh TL. The effect of spinal GABA receptor agonist on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain 70 (1), 15-22 (1997).
271. Loomis CW, Khandwala H, Osmond G, Hefferan MP. Coadministration of intrathecal strychnine and bicuculline effects synergistic allodynia in the rat: an isobolographic analysis. J. Pharmacol. Exp. Ther. 296 (3), 756-761 (2001).
272. Polgar E, Hughes DI, Riddel JS, Maxwell DJ, Puskar Z, Todd AJ. Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain. Pain 104 (1-2), 229-239 (2003).
273. Drew GM, Siddal PJ, Duggan AW. Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn. Pain 109, 379-388 (2004).
274. Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J. Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. Neuroscience 76, 845-858 (1997).
275. Miletic G, Draganic P, Pankratz MT, Miletic V. Muscimol prevents long-lasting potentiation of dorsal horn feld potential in rats with chronic constriction injury exhibiting decreased levels of the GABA transporter GAT-1. Pain 105, 347-353 (2003).
276. Obata K, Yamanaka H, Fukuoka T et al. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats. Pain 101, 65-77 (2003).
277. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol. 44, 475-498 (2004).
278. A receptor subtypes. Nature 451, 330-335 (2008).
279. Rudolph U, Crestani F, Benke D et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (A) receptor subtypes. Nature 401 (6755), 796-800 (1999).
280. A receptor α 1 subtype. Nat. Neurosci. 3 (6), 587-692 (2000).
281. A receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J. Pharmacol. Exp. Ther. 327 (3), 954-968 (2008).
282. A receptor-positive allosteric modulator NS11394 [3'-[5- (1-hydroxy-1-methyl-ethil) -benzoimidazol-1-yl]-biphenyl-2- carbonitrile] with diazepam, zolpidem, bretazenil and gaboxadol in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 327, 969-981 (2008).
283. A receptor subtypes. Nature 451, 330-335 (2008).
284. Zeilhofer HU, Mohler H, Di Lio A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol. Sci. 30 (8), 397-402 (2009).
285. A receptor mimetics-novel antihyperalgesic agents? J. Mol. Med. 8 7, 465-469 (2009).
286. Lynch JW. Native glycine receptor subtypes and their physiological role. Neuropharmacol. 56, 303-309 (2009).
287. Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol. Rev. 84, 1051-1095 (2004).
288. Webb TI, Lynch JW. Molecular pharmacology of the glycine receptor chloride channels. Curr. Pharm Des. 13, 2350-2367 (2007).
289. Lynch JW, Callister RJ. Glycine receptors: a new therapeutic target in pain pathways. Curr. Opin. Investig. Drugs. 7 (1):48-53 (2006).
290. Harvey RJ, Depner UB, Wassle H et al. GlyR α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304 (5672), 884-887 (2004).
291. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU. PGE (2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat. Neurosci. 5 (1), 34-40 (2002).
292. Racz I, Schutz B, Abo-Salem OM, Zimmer A. Visceral, inflammatory and neuropathic pain in glycine receptor α 3-deficient mice. Neuroreport 16 (18), 2025-2028 (2005).
293. Zeilhofer HU. The glycinergic control of spinal pain processing. Cell. Mol. Life Sci. 62, 1-9 (2005).
294. Pellicer F. Lopez-Avila A. Coffeen U. Ortega-Legaspi JM, Del Angel R. Taurine in the anterior cingulated cortex diminishes neuropathic nociception: a possible interaction with the glycine A receptor. Pain 11, 444-451 (2007).
295. Ahrens J, Reyhan D, Leuwer M et al. The nonpsychotropic cannabinoid cannabidiol modelates and directly activates a-1 and α-1-β glycine receptor function. Pharmacology 83 (4), 217-222 (2009).
296. Muth-Sebach U, Hermanns H, Stegmann JU et al. Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system. Eur. J. Pharmacol. 613 (1-3), 68-73 (2009).
297. Dekermendjian K, Wenna N, Aneiros E, Bernström J, Nyman E. Discovery of novel positive allosteric modulators for the inhibitor glycine receptor. Presented at: 38th Annual Meeting for the Society for Neuroscience 729.3, Washingon, DC, USA, 15-19 November 2008.
298. Derbach V, Surprenant A, North RA. 5-HT3 receptors are membrane ion channels. Nature 339, 706-709 (1989).
299. Hoyer D, Clarke DE, Fozard JR et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46, 157-203 (1994).
300. Herrmann S, Stieber J, Ludwig A. Pathophysiology of HCN channels. Pflugers Arch. 454 (4), 517-522 (2007).
301. Barnes NM, Hales TG, Lummis S, Peters JA. The 5-HT3 receptor - the relationship between structure and function. Neuropharmacol. 56, 273-284 (2009).
302. Miquel MC, Emerit MB, Nosjean A et al. Differential subcellular localization of the 5-HT3-A receptor subunit in the rat central nervous system. Eur. J. Neurosci. 15, 449-457 (2002).
303. Pierce PA, Xie GX, Levine JD, Peroutka SJ. 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience 70, 553-559 (1996).
304. Richardson BP, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316, 126-131 (1985).
305. Sufka KJ, Schomburg FM, Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol. Biochem. Behav. 41, 53-56 (1992).
306. Zeitz KP, Guy N, Malmberg AB et al. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J. Neurosci. 22, 1010-1019 (2002).
307. Espejo EF, Gil E. Antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5-HT3 receptors. Brain Res. 788, 20-24 (1998).
308. Giordano J, Dyche J. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacol. 28, 423-427 (1989).
309. Giordano J, Rogers LV. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur. J. Pharmacol. 170, 83-86 (1989).
310. Eschalier A, Kayser V, Guilbaud G. Influence of a specific 5-HT3 antagonist on carrageenan-induced hyperalgesia in rats. Pain 36, 249-255 (1989).
311. 3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury. J. Neurosci. Res. 87, 418-424 (2009).
312. Fozard JR. Neuronal 5-HT receptors in the periphery. Neuropharmacol. 23, 1473-1486 (1984).
313. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur. J. Pharmacol. 354, R13-14 (1998).
314. 3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth. Analg. 97, 1474-1478 (2003).
315. Ye JH, Mui WC, Ren J et al. Ondansetron exhibits the properties of a local anesthetic. Anesth. Analg. 85, 1116-1121 (1997).
316. Ambesh SP, Dubey PK, Sinha PK. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study. Anesth. Analg. 98, 197-199 (1999).
317. 3 receptor antagonists.
318. ® in mice with spinal nerve ligation. Anesth. Analg. 101, 793-799 (2005).
319. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 74 (6), 363-396 (2004).
320. 2+ modulation of human neuronal α3 nicotinic receptors. J. Pharmacol. Exp. Ther. 286 (1), 311-320 (1998).
321. Nelson ME, Lindstrom J. Single channel properties of human α3 AChRs: impact of β2, β4 and α5 subunits. J. Physiol. 516 (3), 657-678 (1999).
322. Haberberger RV, Bernardini N, Kress M, Hartmann P, Lips KS, Kummer W. Nicotinic acetylcholine receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat. Auton. Neurosci. 113, 32-42 (2004).
323. Khan I, Osaka H, Stanislaus S. Nicotinic acetylcholine receptors distribution in relation to spinal neurotransmission pathways. J. Comp. Neurol. 467 (1), 44-59 (2003).
324. Aceto MD, Bagley RS, Dewey WL, Fu TC, Martin BR. The spinal cord as a major site for the antinociceptive action of nicotine in the rat. Neuropharmacol. 25, 1031-1036 (1986).
325. Badio B, Daly J W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45, 563-569 (1994).
326. Marubio LM, Arroyo-Jimenez MM, Cordero-Erausquin M et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398, 805-810 (1999).
327. Bitner RS, Nikkel AL, Curzon P et al. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. 871, 66-74 (2000).
328. Damaj MI, Fonck C, Marks MJ et al. Genetic approaches identify differential roles for α4b2 nicotinic receptors in acute models of antinociception in mice. J. Pharmacol. Exp. Ther. 321, 1161-1169 (2007).
329. Wonnacott S, Soliakov L, Wilkie G, Redfern P, Marshall D. Presynaptic nicotinic acetylcholine receptors in the brain. Drug Dev. Res. 38, 149-159 (1996).
330. Rueter LE, Kohlass KL, Curzon P, Surowy CS, Meyer MD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 103 (3), 269-276 (2003).
331. Kesingland AC, Gentry CT, Panesar MS et al. Analgesic prolfile of the nicotinic acetylcholine receptor agonists, (+) -epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 86 (1-2), 113-118 (2000).
332. Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. 801 (1-2), 158-163 (1998).
333. Jordan KG, Hauser TA, Fedorov N, Traina VM, Bencherif M. TC-6499: an orally effective and selective α-4-β-2 neuronal nicotinic receptor agonist with anti-allodynic activity. 37th Annual Meeting of the Society for Neuroscience abstr. 39.7, San Diego, CA, USA, 3-7 November 2007.
334. Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochemical Pharmacol. 74, 1092-1101 (2007).
335. Taly A, Cirringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 8, 733-750 (2009). Recent and interesting review on nicotinic receptors as drug targets in the nervous system.
336. Blackburn-Munro G, Dalby-Brown W, Mirza N R, Mikkelsen JD, Blackburn-Munro RE. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11 (1), 1-20 (2005).
337. Cattabeni F. Ralfinamide. IDrugs 7 (10), 935-939 (2004).
338. Colombo E, Curatolo L, Caccia C, Faravelli L et al. Ralfinamide acts through NMDA receptor complex: a central role for chronic pain treatment. Eur. J. Pain, 11 (1), 152-153 (2007).
339. Barbieri M, Bregola G, Buzzi A et al. Mechanisms of action of CHF3381 in the forebrain. Br. J. Pharmacol. 139, 1333-1341 (2003).
340. Simpson DM, Brown SJ, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology, 70, 2305-2313 (2008).
341. Simpson DM, Estanislao L, Brown SJ. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. Pain Symptom. Manag. 35, 299-306 (2008).
342. Rami HK, Thompson M, Stemp G et al. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg. Med. Chem. Lett. 16 (12) 3287-3291 (2006).
343. Swanson DM, Dubin AE, Shah C et al. Identification and biological evaluation of 4- (3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl) amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48 (6), 1857-1872 (2005).
344. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N- (4-tertiarybutylphenyl) -4- (3-cholorphyridin-2-yl) tetrahydropyrazine -1 (2H) -carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo vharacterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 306, 387-393 (2003).
345. Culshaw AJ, Bevan S, Christiansen M et al. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J. Med. Chem. 49 (2), 471-474 (2006).
346. Walpole C S J, Bevan S, Bovermann G et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem. 37 (13), 1942-1954 (1994).
347. Walker KM, Urban L, Medhurst SJ et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharm. Exp. Ther. 304, 56-62 (2003).
348. Gauvin DM, Mikusa J, Baker S et al. A-967079, a potent and selective TRPA1 antagonist, is efficacious in rat preclinical pain models. Presented at: 39th Annual Meeting of the Society for Neuroscience. Chicago, IL, USA, 17-21 October 2009 (Abstract 761.3).
349. Watanabe S, Ohmi M, Inoue T, Nonomura C, Fujiiuchi A. Identification of novel TRPM8 channel antagonists. Presented at: 39th Annual Meeting of the Society for Neuroscience. Chicago, IL, USA, 17-21 October 2009 (Abstract 73.7).
350. th Annual Meeting of the American Academy of Neurology. 11-14 April 2008 (Abstract P03, 179).
351. Zhang, S-H, Blech-Hermoni Y, Seltzer, Z, Faravelli L et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain 39 (2), 293-305 (2008).
352. + currents in dorsal root ganglion neurons. Eur. J. Pharmacol. 510 (3), 197-208 (2005).
353. + channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exper. Neurol. 208, 63-72 (2007).
354. Brochu RM, Dick IE, Tarpley JW et al. Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol. Pharmacol. 69 (3), 823-832 (2006).
355. Shao PP, Ok D, Fisher MH et al. Novel cyclopentane dicarboxamide sodium channel blocker, as potential treatment for chronic pain. Bioorg. Med. Che. Lett. 15 (7), 1901-1907 (2005).
356. v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA 104 (20), 8520-8525 (2007).
357. v1.8 selective compounds and evidence that channel subtype block is sufficient for efficacy in several rat pain models.
358. v1.7 blockers can exhibit good potency in a rat model for neuropathic pain.
359. v1.7. Biochemistry 46 (50), 14693-14703 (2007).
360. v1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth. Analg. 109, 951-958 (2009).
361. Zamponi GW, Feng Z-P, Zhang L et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 19, 6467-6472 (2009).
362. Knutsen L J S, Hobbs CJ, Earnshaw CG et al. Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 17 (3), 662-667 (2007).
363. Yamamoto T, Niwa S, Ohno S et al. The structure activity relationship study on the water-soluble 1, 4-dihydropyridine derivatives blocking N-type calcium channels. 20th International Symposium on Medicinal Chemistry abstr. P150, 31 August 2008.
364. Saito Y, Kirihara Y, Hashimoto T et al. Spinal antinociceptive effects of a new calcium channel blocker, AGS1164, in rats. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, 8-12 November 2003.
365. Koganei H, Fujita S, Iwayama S et al. Analgesic effects of a novel compound which posseses N-type calcium channel blocking activity. 32rd Annual Meeting of the Society for Neuroscience abs. 656.2, Orlando, FL, 2-7 November 2002.
366. Yang Z-Q, Barrow JC, Shipe WD et al. Discovery of 1, 4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J. Med. Chem. 51 (20), 6471-6477 (2009).
367. Goodchild CS, Nelson J, Cooke I, Ashby M, Jackson K. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med. 9 (7), 939-949 (2008).
368. Wickenden AD, McNaughton-Smith G, Roeloffs R, London B, Clark S. ICA-27243: a novel, potent, and selective KCNQ2/Q3 potassium channel activator. Presented at: 35th Annual Meeting of the Society for Neuroscience Washington, DC, USA, 12-16 November 2005 (Abstract 153.13).
369. Roeloffs R, Harrison W, Mahoney JH, Leach C, Robinette L. In vivo profle of a KCNQ2/3 selective versus a pan-KCNQ activator in rodent models of pain. Presented at: 38th Annual Meeting of the Society for Neuroscience Washington, DC, USA 15-18 November 2008 (Abstract 631.4).
370. Wickenden AD, Krajewski JL, London B et al. N- (6-chloro-pyridin-3-yl) -3, 4-difluorobenzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol. Pharmacol. 73 (3), 977-986 (2008).
371. Wu YJ, He H, Sun L-Q et al. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers. J. Med. Chem. 47 (11), 2887-2896 (2004).
372. v-β-1-subunit interactions are antianalgesic in vivo. Presented at: 37th Annual Meeting of the Society for Neuroscience San Diego, CA, 3-7 November 2007 (Abstract 469.30).
373. Mangat M, Schmudermaier M, Dubé GR, Schmudermaier B, Gervais F, Gustorff B. The effects of PPC-5650, an ASIC1a antagonist on hyperalgesia in a human inflammatory pain model. Presented at: The 11th International Conference on the Mechanisms and Treatment of Neuropathic Pain 6-8 November 2008.
374. Simard B, Paquet M, Elagoz A et al. PPC-5692, a novel and selective ASIC1a antagonist, exerts analgesic effects across multiple animal pain models. Presented at: 38th Annual Meeting for the Society for Neuroscience Washington, DC, USA, 15-19 November 2008 (Abstract 857.14).
375. Bordet T, Buisson B, Michaud M et al. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy induced neuropathy. J. Pharmacol. Exp. Therap. 326 (2), 623-632 (2008).
376. Walters R, Bradford A P J, Fischer J et al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br J Clin Pharmacol. 53 (3), 305-311 (2002).
377. Hu L-Y, Guo J, Magar SS et al. Synthesis and pharmacological evaluation of N- (2, 5-disubstituted phenyl) -N-3-substituted phenyl) -N-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. J. Med. Chem. 40, 4281-4289 (1997).
378. Tarral A, Dostert P, Guillevic Y et al. Pharmacokinetics and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. J. Clin. Pharm. 43 (8), 901-911 (2003).
379. Villetti G, Bregola G, Bassani F et al. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacol. 40, 866 (2001).
380. Zucchini S, Buzzi A, Bergamaschi M et al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. Neuroreport 13, 2071-2074 (2002).
381. Rammes G. Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications. Exp. Rev. Clin. Pharmacol. 2 (3), 231-238 (2009).
382. Chen SR, Samoriski G, Pan HL. Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. Neuropharmacol. 57 (2), 121-126 (2009).
383. Malyshkin AA, Medvedev IO, Danysz W et al. Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats. Eur. J. Pharmacol. 519 (1-2), 80-85 (2005).
384. Klein T, Magerl W, Hanschmann A et al. Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur. J. Pain (Amsterdam, Netherlands) 12 (1), 17-29 (2007).
385. Erichsen HK, Blackburn-Munro G. Pharmacological characterisation of the spared nerve injury model of neuropathic pain. Pain 98 (1-2), 151-161 (2002).
386. Blackburn-Munro G, Bomholt S, Erichsen HK et al. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacol. 47 (3), 351-362 (2004).
387. Gormsen L, Finnerup NB, Almqvist PM et al. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth. Analg. 108 (4), 1311-1319 (2009).
388. Kasper C, Pickering DS, Mirza O et al. The structure of a mixed GluR2 ligand-binding core dimer in complex with (S) -glutamate and the antagonist (S) -NS1209. J. Mol. Biol. 357 (4), 1184-1201 (2006).
389. Pinza M, Farina C, Cerri A et al. Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1, 2-a]imidazole-2, 5 (3H, 6H) -diones, a novel class of potent cognition enhancers. J. Med. Chem. 36 (26), 4214-4220 (1993).
390. Farina C, Gagliardi S, Ghelardini C et al. Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain. Bioorg. Med. Chem. 16 (6), 3224-3232 (2008).
391. Bonanno G, Misiano P, Bonifacino T et al. Effects of BND-11624 at ionotropic and metabotropic glutamatergic receptors regulating neurotransmitter release in the rat CNS. Annual Meeting of the Society for Neuroscience. Atlanta, US, 17 November 2008 (Abstract 368.2/JJ27).
392. Farkas S, Horvath C, Nagy J et al. RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA, 8-12 November 2009.
393. Barta-Szalai G, Borza I, Bozo E et al. Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 14 (15), 3953-3956 (2004).
394. Palecek J, Neugebauer V, Carltons M, Iyengar S. Willis WD. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 111 (1-2), 151-161 (2004).
395. Baudy RB, Butera JA, Abou-Gharbia MA et al. Prodrugs of perzinfotel with improved oral bioavailability. J. Med. Chem. 52 (3), 771-778 (2009).
396. Perez-Medrano A, Donnelly-Roberts DL, Honore P et al. Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain. J. Med. Chem. 52, 3366-3376 (2009).
397. 7 antagonists. J. Med. Chem. 49, 3659-3666 (2006).
398. 3/P2X2/3 antagonist for the treatment of pain. Bioorg. Med. Chem. Lett. 19 (6), 1632-1635 (2009).
399. Crean CS, Yerxa BR, Bednarski K et al. Analgesic effects of INS48506, a P2X (3) receptor antagonist, in models of acute, inflammatory and neuropathic pain. 33rd Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA, 8-12 November 2003.
400. 3 and P2X2/3 purinergic receptors. 37th Annual Meeting of the Society for Neuroscience Abstr. 820.13, San Diego, CA, USA, 3-7 November 2007.
401. Rueter LE, Curzon P, Kohlhaas K, Gauvin D, Honore P. ABT-894, a neuronal nicotinic receptor agonist, with an improved therapeutic window in preclinical models of neuropathic pain vs. gastrointestinal and CNS side effects. 38th Annual Meeting for the Society for Neuroscience. Washington, DC, USA, 15-19 November 2008 (Abstract 856.20).
402. Lippiello PM, Gatto GJ, Jordan KG, Bencherif M. Novel neuronal nicotinic receptor selective compounds for the treatment of acute, chronic and neurpathic pain. Eur. Neuropsychopharmacol. 17 (4), 252 (2007).
403. Holtman J, Johnson-Hardy J, Crooks P, Chakraborty U, Wala E. Novel opioidnicotinic combination drug therapy for pain. 28th Annual Scientific Meeting of the American Pain Society 29 Abstract. 216, 7 May 2009.
404. Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 103 (3), 269-276 (2003).
405. Dunlop J, Vasilyev D, Lu P, Cummons T, Bowlby MR. Hyperpolarization- activated cyclic nucleotide-gated (HCN) channels and pain. Curr. Pharm. Des. 15, 1767-1772 (2009).
406. Jiang YQ, Sun Q, Tu HY, Wan Y. Characteristic of HCN channels and their participation in neuropathic pain. Neurochem. Res. 33, 1979-1989 (2008).
407. Maher MP, Wu N-T, Guo H-Q, Dubin AE, Chaplan SR, Wickenden AD: HCN channels as targets for drug discovery. Comb. Chem. High Through. Screen. 12 (1), 64-72 (2009).